Abstract | BACKGROUND: OBJECTIVE: METHODS: This was a prospective study of patients with acute cerebral infarction within 48 h of onset and treated between July 2012 and July 2016 at three hospitals in China. The patients were randomized to routine treatments (control group) versus routine treatments and Kudiezi injection ( Kudiezi group). The National Institutes of Health Stroke Score was assessed on days 1, 3, 5, 7, and 14. The patients were tested for serum levels of pro- and anti-inflammatory cytokines (S100 calcium-binding protein B, neuron-specific enolase, interleukin-6, interleukin-10, interleukin-18, and matrix metaloproteinase-9; by enzyme-linked immunosorbent assay) immediately after admission and on days 3, 5, and 14. RESULTS: CONCLUSION:
|
Authors | Xuemei Liu, Xianglan Jin, Baoxin Chen, Xiaohan Liu, Xiao Liang, Xiaolei Fang, Hongyun Wu, Xiaoyu Fu, Hong Zheng, Xiao Ding, Na Duan, Yunling Zhang |
Journal | Disease markers
(Dis Markers)
Vol. 2018
Pg. 7936736
( 2018)
ISSN: 1875-8630 [Electronic] United States |
PMID | 30245755
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Biomarkers
- Drugs, Chinese Herbal
- Interleukins
- S100 Calcium Binding Protein beta Subunit
- S100B protein, human
- kudiezi
- MMP9 protein, human
- Matrix Metalloproteinase 9
|
Topics |
- Acute Disease
- Aged
- Biomarkers
(blood)
- Cerebral Infarction
(blood, complications, drug therapy)
- Drugs, Chinese Herbal
(pharmacology)
- Female
- Humans
- Inflammation
(blood, etiology)
- Interleukins
(blood)
- Male
- Matrix Metalloproteinase 9
(blood)
- Middle Aged
- Prospective Studies
- S100 Calcium Binding Protein beta Subunit
(blood)
- Treatment Outcome
|